Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from 4D Molecular Therapeutics ( (FDMT) ) is now available.
On March 25, 2026, 4D Molecular Therapeutics appointed Chief Financial Officer Kristian Humer as its Principal Accounting Officer, consolidating key financial leadership roles under a single executive. He replaces Ashoo Gupta in this capacity, who remains Vice President, Finance and Controller, signaling continuity in the finance organization alongside the leadership shift.
Humer, 51, joined the company as CFO and Principal Financial Officer in November 2025, bringing extensive experience from prior CFO roles at biotechnology firms Foghorn Therapeutics and Viridian Therapeutics. His earlier tenure as a managing director in Citigroup’s Healthcare Investment Banking Group adds capital markets and deal-making expertise, which may strengthen 4D Molecular Therapeutics’ financial strategy and support its growth ambitions.
The most recent analyst rating on (FDMT) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
FDMT scores below average primarily due to persistent losses and ongoing cash burn despite a comparatively strong, low-debt balance sheet. Technical signals are mixed with modest near-term weakness, and valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines using engineered adeno-associated virus vectors for a range of serious diseases. The company operates in the biopharmaceutical sector, targeting unmet medical needs through innovative gene therapy platforms and clinical-stage therapeutic candidates.
Average Trading Volume: 782,463
Technical Sentiment Signal: Buy
Current Market Cap: $476.3M
Learn more about FDMT stock on TipRanks’ Stock Analysis page.